How are the “same” cancers treated differently? Not all gleason scores of 6, 7, or 8+ can be treated equally. How do we individualize the care with the diagnostic tools available to us, when patients present with similar clinicopathologic characteristics?
Read MoreControversy remains surrounding the use of the PSA test to screen for prostate cancer. This is due to the belief that the PSA test may lead to over-diagnosis and over-treatment in men with low-grade, less aggressive forms of the disease. Clinicians have been long awaiting a new approach to screen for prostate cancer because the current PSA test is simply not accurate enough.
Read MoreWe've come a long way. There have been many innovations when it comes to prostate cancer detection. Here's what men need to be aware of.
Read More
